Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06585410
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-03
Brief Title:
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma CSCC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma CSCC a type of skin cancer Cemiplimab works by helping the immune system to kill cancer cells It binds to a protein called programmed cell death-1 PD-1 on the surface of certain immune cells
The main purpose of this study is to compare how well cemiplimab works compared to surgery when injected into the lesion
The study is looking at
The side effects cemiplimab might cause
How well cemiplimab works
The main purpose of this study is to compare how well cemiplimab works compared to surgery when injected into the lesion
The study is looking at
The side effects cemiplimab might cause
How well cemiplimab works
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None